Healthcare / BiotechnologyNasdaqCM
$19.47
-0.32 (-1.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-24.8M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$26M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-113.4%
↓Gross Margin
N/A
•Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.97x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-21.1M · FCF $-20.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-21.1M | $-21.1M | $-30.2M | $-34.1M | $-48.6M | $-36.8M | $-20.1M |
| EBITDA | $-20.9M | $-20.9M | $-28.7M | $-32.6M | $-47.0M | $-36.8M | $-19.2M |
| EPS | -16.72 | -16.72 | -24.00 | -24.40 | -31.60 | -26.60 | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.08 | 0.08 | 0.10 | 0.10 | 0.08 | — | -0.01 |
| Current Ratio | 14.39 | 14.39 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-20.5M | $-20.5M | $-24.8M | $-32.2M | $-39.3M | $-32.3M | $-18.9M |
| Returns | |||||||
| ROE | -113.4% | -113.4% | -78.6% | -52.5% | -47.0% | -25.1% | 35.6% |
| Valuation | |||||||
| P/B | 1.32 | 1.32 | 0.33 | 0.33 | 0.48 | — | — |
| Growth & Yield | |||||||
| EPS Growth | 30.3% | 30.3% | 1.6% | 22.8% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+209.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-24.00 → -16.72
Residual
+209.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.